Predicting Progression in Barrett's Esophagus: Is the Holy Grail within Reach?

Research output: Contribution to journalReview articlepeer-review


Risk stratification in Barrett's esophagus may allow aggressive management of those at "high risk" and reduction in surveillance in at "low" risk. Davison et al. report the results of the independent validation of a multibiomarker panel (TissueCypher assay) performed on biopsy tissue, in a case control study. "High-risk" patients progressed 5 times more than those at "low risk." Sensitivity and specificity for "high-risk" patients were 29% and 86% with a positive predictive value of 23%. A negative predictive value of a "low-risk" score was 96%. These findings may allow more intensive surveillance in those at "high risk." Despite some limitations, this assay is a potentially major advance in the management of Barrett's esophagus patients without dysplasia.

Original languageEnglish (US)
Pages (from-to)841-842
Number of pages2
JournalAmerican Journal of Gastroenterology
Issue number6
StatePublished - Jun 1 2020

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Predicting Progression in Barrett's Esophagus: Is the Holy Grail within Reach?'. Together they form a unique fingerprint.

Cite this